The long-term outcome of tacrolimus in cadaveric kidney transplantation from non-heart beating donors
| Autor: | Nobuyuki Fukuhara, Osamu Kamihira, Shinichi Ohshima, Naoki Nishiyama, Ryohei Hattori, Shin Yamada, Yoshinari Ono, Tsuneo Kinukawa |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Kidney Methylprednisolone Tacrolimus Ischemia medicine Cadaver Humans Longitudinal Studies Survival rate Kidney transplantation Acute tubular necrosis Transplantation business.industry Significant difference Graft Survival Kidney Tubular Necrosis Acute medicine.disease Kidney Transplantation Tissue Donors Surgery Survival Rate medicine.anatomical_structure Treatment Outcome Cyclosporine Tissue and Organ Harvesting Kidney Failure Chronic Graft survival Female Cadaveric spasm business Immunosuppressive Agents Follow-Up Studies |
| Zdroj: | Clinical transplantation. 19(2) |
| ISSN: | 0902-0063 |
| Popis: | Tacrolimus (Tac), developed in 1990, has been applied as an immunosuppressive agent for liver, heart, and kidney transplantation and is known to have more powerful immunosuppressive effects than cyclosporine (CyA). To evaluate the efficacy of Tac in cadaveric kidney transplants from non-heart beating donors, we present the long-term outcome of patients receiving kidneys with ischemic damage, and compared it with that of CyA. Between July 1990 and December 2000, 55 patients with end-stage renal disease received kidneys from non-heart beating donors (Maastrichy category 3) and were treated with Tac and steroid immunosuppressive therapy. During the same period, we also performed 137 non-heart beating cadaveric renal transplants treated with CyA-based immunosuppressive therapy. The patient survival rate was 98% at 1 yr and 96% at 3–10 yr in the Tac group, and 97% at 1–3 yr, 93% at 5 yr and 85% at 10 yr in the CyA group. The graft survival rate was 91% at 1 yr, 80% at 3 yr, 63% at 5 yr and 34% at 10 yr in the Tac group, and 88% at 1 yr, 75% at 3 yr, 63% at 5 yr and 49% at 10 yr in the CyA group. There was no significant difference in either patient or graft survival rates between the two groups. Acute early rejection in the Tac group was less than that in the CyA group but acute tubular necrosis was the same in both groups. This indicates that Tac is available for cadaveric kidney transplants from non-heart beating donors. In conclusion, Tac is available as an immunosuppressive agent even for kidney transplants from non-heart beating donors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|